EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis

Andrew Proudfoot iD, Sarah Duffy, Justin Sinclair, Jason Abbott iD, Mike Armour iD

Australian and New Zealand Journal of Obstetrics and Gynaecology · 2024

DOI: 10.1111/ajo.13804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2024. Verfasst von Andrew Proudfoot und 4 weiteren Autor:innen. Beteiligte Einrichtung: NICM Health Research Institute, Western Sydney University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Endometriosis, Medical Marijuana, Cannabinoids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People with endometriosis use cannabis to manage their symptoms. This study aimed to identify costs, modes of administration, product composition, and self‐reported effectiveness for those accessing medicinal cannabis in Australia. There were 192 survey responses analysed. Most (63.5%) used a ‘cannabis clinic’ doctor, incurring an initial consultation cost of $100–$200+ (10.2% Medicare bulk‐billed) and median cannabinoid medicine costs of $300AUD per month. Cost was a major barrier to access, necessitating reducing dosage (76.1%) and/or consuming illicit cannabis (42.9%), despite a prescription. Most (77%) medical consumers used two or more cannabis products, with delta‐9‐tetrahydrocannabinol predominant oil and flower products most frequently prescribed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndometriosisMedical MarijuanaCannabinoidsHumansFemaleAustraliaAdultHealth Services AccessibilitySurveys and QuestionnairesMiddle AgedYoung AdultDronabinolAustralasian People

Stichwörter der Autor:innen

CBMPadministration methodcannabischronic paindoseendometriosisinsurance

Substanzen

Medical MarijuanaCannabinoidsDronabinol

Autor:innen und Institutionen

  • NICM Health Research Institute, Western Sydney University, Sydney, New South Wales, Australia.
  • School of Business, Western Sydney University, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, Health and Medicine, University of New South Wales, Sydney, New South Wales, Australia.
  • Gynaecological Research and Clinical Evaluation (GRACE) Unit, Royal Hospital for Women, Sydney, New South Wales, Australia.
  • Prince of Wales Private Hospital, Sydney, New South Wales, Australia.
  • Medical Research Institute of New Zealand (MRINZ), Wellington, New Zealand.

ORCID-Profile: Andrew Proudfoot, Jason Abbott, Mike Armour

Zitieren

APA

Proudfoot, A., Duffy, S., Sinclair, J., Abbott, J., & Armour, M. (2024). A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.13804

Vancouver

Proudfoot A, Duffy S, Sinclair J, Abbott J, Armour M. A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2024. doi:10.1111/ajo.13804

BibTeX
@article{Proudfoot2024,
  author = {Proudfoot, Andrew and Duffy, Sarah and Sinclair, Justin and Abbott, Jason and Armour, Mike},
  title = {A survey of cost, access and outcomes for cannabinoid‐based medicinal product use by Australians with endometriosis},
  journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
  year = {2024},
  doi = {10.1111/ajo.13804}
}
Kostenlos starten →